ѱ̿Ǿǰȸ Ʈ
|
|
|
ڷ |
Ǿǰ ۿ м ý ȭ
ǰǾǰó(ó ) ŷڼ ִ Ǿǰ Ȯϱ Ͽ ȯǹ(EHR, Electronic Health Record) ۿ м 뵥(CDM, Common Data Model) Ȱ 'Ǿǰ ۿ м ý' ȭѴٰ .
ش ߾Ӵ 5 20 ȯ Ƿ CDM' ȯϿ ߰ϰ, `22 27 Ǿǰ 200 ȯ Ƿ ͷ Ͽ Ǿǰ ۿ м Ȱ ̴.
`16 4(, ϴ, 湫, ), `17 5(߾Ӵ, λ, , , )
CDM' Ȱ Ͱ Ǹ ۿ Ǿǰ ۿ밣 ΰ踦 Ȯ ľ ƴ϶ ۿ ν Ȯϰ Ƿ ְ, ǰ ߿ Ȱ Ǿǰ Ǿǰ Ͽ ӻ̳ Ǿǰ ȹ ȴ...... |
|
ǰȸ |
Ǿǰ ӻ Ƿ ס() ǰȸ
Ǿǰ ӻ ߴϰ ġ ̻ Ͽ, ӻ Ƿڰ ϰ Կ ־ ؾ ϱ Ǿǰ ӻ Ƿ ס(οξȳ) ϰ
Ǿǰ ӻ Ƿ ()
ǰ Ͻ : ~ 7 / 27 ()
ǰ ó : info@kobia.kr
|
|
|
ǰȸ |
Ǿǰ(̿ùз) 㰡 ȡǰȸ
Ǿǰ(̿ùз)( ̿ùз) ǰ㰡 㰡 濡 ̿ùз 㰡 Ͽ, 㰡 ̿ùз 㰡 ʿ
̿Ǿǰ ֱ 㰡 ȯ Ǿǰ(̿ùз) 㰡 ȡ() ǰ ȸϰ
Ǿǰ(̿ùз) 㰡
ǰ Ͻ : ~ 7 / 26 ()
ǰ ó : info@kobia.kr
|
|
|
̿Ǿǰ 㰡ɻܰ Ĺοȸ Ȯ
Ĺοȸ
- : ̿Ǿǰ, Ѿ() ž ű 㰡û ο
- ֽñ ֿ䳻
(D80) οȸ : ڷ ǰ, ϻ, ڹȸ
㰡 (D100) οȸ : ֿ 㰡() 㰡
- : Ǵ ȭȸ
Ĺοȸ Ȯ
- Ȯ : ȿɻ(ȿȿ, 뷮) ǰ㰡
- ֽñ : (D45), 㰡 (D55)
- Ȯ ñ : 2017.7.19. ο Ȯ
ȳ Ȯ |
|
ڷ |
ǰǾǰо 衤˻ Ϻΰ
2017 ǰǾǰ鼭 ٷΰ |
|
|
|
|
|
2017 ũξƼ ΰյ Ƿ İ
Ǻο Ƿ ؿ ϱ Ͽ ܱ ܰ 'ڸ *' ǽϰ , 2017 ڸ ũξƼƴѹα Ͽ 'ũξƼ ΰ յ Ƿ 'İ ϰ
[ũξƼ Ƿ» İ߰]
- : 2017 10, 34 () * İ ο 氡
- 湮 : ũξƼ(ڱ)
- ֿȰ : 籹 Ǻΰ MOU ü, ֿλ , , 1:1 Ͻ ȸ, -ũξƼ Ƿ ̳
ϴ ü ȮϽð ~17.7.27() ڿ Ͽ ֽñ ٶϴ.......
- inae.kim@kobia.kr
- : 02-725-8432
|
|
|
ż
ǰɻ( , ɻ) Ƿå ϴ ϱ ( ) Ѵ.
ż ǹ dz 10 dz Ͽ ġ․ϸ, 7 14 Ǻο յ Kick-off ȸǸ ߴ.
ֿ
ž ż İ 㸸ȯ ǰ 㰡 ʰ ü ......ڷ
|
|
|
|
|
|
û |
|
ǰ |
ӻ |
ܰ |
ѹ̾ǰ() |
20170720 |
Ź Ŭĸ̵(TC) ʱ ȯڸ ȭп ȣ߱ ġῡ ־ ʱ(Pegfilgrastim) SPI-2012 (ö, Eflapegrastim) , , Ȱ ӻ(RECOVER)
|
3 |
HM10460A |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
VOSEVI
NDA #209195 |
SOFOSBUVIR;
VELPATASVIR
VOXILAPREVIR |
Ź/ź |
GILEAD SCIENCES INC |
07/18/2017 |
LUSDUNA
NDA #208722 |
INSULIN GLARGINE |
Ǵ |
MERCK SHARP DOHME |
07/19/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Spherox |
spheroids of human autologous matrix-associated chondrocytes |
Cartilage Diseases |
10/07/2017 |
|
|
|
|
PMDA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Parmodia? tablets 0.1 mg |
Kowa Corporation |
Pemafibrate |
2017.07.03 |
Olumiant tablets 4 mg
tablets 2 mg |
Japan Eli Lilly Co., Ltd., |
Baricitinib |
2017.07.03 |
Amenalief? tablets 200 mg |
Maruho Corporation |
Amenamevir |
2017.07.03 |
CANALIA? Combination Tablets |
Mitsubishi Tanabe Pharma Corporation |
Teneligliptin / Canagliflozin |
2017.07.03 |
Bipresso sustained release tablet 50 mg
sustained release tablets 150 mg |
Astellas Pharma Inc., |
Quetiapine fumarate |
2017.07.03 |
Difolta? injection 20 mg |
Mundipharma Corporation, |
Pralatrexate |
2017.07.03 |
Istodax? for intravenous infusion 10 mg |
Celgene Co., Ltd., |
Romidepsin |
2017.07.03 |
Spinraza intrathecal injection 12 mg |
Biogen Japan Co., Ltd., |
Nusinersen sodium |
2017.07.03 |
Jadenu granule 90 mg
granule 360 mg |
Novartis Pharma Corporation, |
Deferasirox |
2017.07.03 |
|
|
|
|
|
|
|
Clinical.gov ̱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03223610 |
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma |
Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma |
Drug: Venetoclax
Drug: Ibrutinib
Drug: Prednisone
Drug: Obinutuzumab
Drug: Revlimid (lenalidomide) |
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03223103 |
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma |
Glioblastoma |
Drug: Poly-ICLC
Device: Tumor Treating Fields
Biological: Peptides |
Adilia M Hormigo
NovoCure Ltd.
Icahn School of Medicine at Mount Sinai |
Phase 1 |
NCT03226249 |
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma |
Classical Hodgkin Lymphoma
Lymphocyte-Depleted Classical Hodgkin Lymphoma
Lymphocyte-Rich Classical Hodgkin Lymphoma
Mixed Cellularity Classical Hodgkin Lymphoma
Nodular Sclerosis Classical Hodgkin Lymphoma |
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Radiation: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Vinblastine Sulfate |
Northwestern University
National Cancer Institute (NCI) |
Phase 2 |
|
|
Clinical.gov |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
Nation |
NCT03227263 |
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study |
Hemorrhagic Hereditary Telangiectasia (HHT) |
Drug: Bevacizumab
Drug: sodium chloride 0.9% |
Hospices Civils de Lyon |
Phase 3 |
|
NCT03225924 |
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy |
DLBCL |
Drug: Entospletinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone |
The Lymphoma Academic Research Organisation |
Phase 1
Phase 2 |
|
|
|
|
|
|
|
|
̿IT÷ '17 ű ȳ |
̿IT÷ 2017 ű |
2017 Ͽ 12 ܿ Ʈ, εþ, Űź 3 ߰ Դϴ. ɰ ̿ Ź 帳ϴ. |
|
̿IT÷ ȳ |
2017 ֿ ǿ(̱, , ߱) ü 㰡 (2017 ÷ܹ̿Ǿǰ ؿ ̿IT÷ ) Ӱ ǽ Դϴ. û ٶϴ. |
'' ̶? |
̿Ǿǰ ؿ 㰡 ִ
1:1(ñ: Ƿ ü) |
|
|
Ͻô ü ȸ Ǵ ̿IT÷ Ȩ ̿IT÷ û ȮϽð,
̿Ǿǰ ؿ Ƿڼ ۼϽþ ̸(bpis@kobia.kr) ûϽñ ٶϴ.
ִ 5 ȭ, (ܰ躰) Ƿڰ մϴ. |
|
̿IT÷ () ٷΰ |
|
̿IT÷ ٷΰ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|